title: Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
abstract: Influence of age and sex on chemotherapy-related toxicity was evaluated in children (3-9 years), adolescents (10-17 years), and adults (up to 40 years) with localized Ewing sarcoma (ES) enrolled in the ISG/SSG III protocol. Treatment was based on vincristine, doxorubicin, cyclophosphamide, ifosfamide, dactinomycin, and etoposide. High-dose chemotherapy with busulfan and melphalan was given in poor responder patients. The analysis was based on 2191 courses of standard chemotherapy and 230 patients. A lower risk of G4 leukopenia and thrombocytopenia, hospitalization, febrile neutropenia, and red blood cell (RBC) transfusions was observed in males. Use of granulocyte colony-stimulating factor (G-CSF) was more frequent in adults, while children more often received RBC transfusions. A significant correlation between sex and chemotherapy-related toxicity was observed in the study, whereas no significant differences in terms of bone marrow toxicity can be expected according to patient age. Further studies should analyse the role of pharmacokinetics, pharmacogenomics, and clinical characteristics.
authors.forename: Anna
authors.initials: A
authors.lastname: Paioli
authors.forename: Roberto
authors.initials: R
authors.lastname: Luksch
authors.forename: Franca
authors.initials: F
authors.lastname: Fagioli
authors.forename: Angela
authors.initials: A
authors.lastname: Tamburini
authors.forename: Marilena
authors.initials: M
authors.lastname: Cesari
authors.forename: Emanuela
authors.initials: E
authors.lastname: Palmerini
authors.forename: Massimo Eraldo
authors.initials: ME
authors.lastname: Abate
authors.forename: Emanuela
authors.initials: E
authors.lastname: Marchesi
authors.forename: Alba
authors.initials: A
authors.lastname: Balladelli
authors.forename: Loredana
authors.initials: L
authors.lastname: Pratelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferrari
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D015080:Mesna / Q000008:administration & dosage; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000473:pathology; D012737:Sex Factors; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D015080:Mesna; D008558:Melphalan; D007069:Ifosfamide
keywords: Age,; Chemotherapy,; Ewing sarcoma,; Sex,; Toxicity